Prostatype Genomics

Interim report first half of the year

2026

Prostatype Genomics AB

Summary

First half of 2026

1 January – 30 June 2026

- Net sales amounted to 457 TSEK (246)
- EBITDA (earnings before interest, taxes, depreciation, and amortization) amounted to -16,382 TSEK (-18,971)
- Cash flow from operating activities amounted to -14,175 TSEK (-17,079)
- Total cash flow for the period amounted to -8,681 TSEK (3,517)
- Earnings per share amounted to -0.29 SEK (-1.42)*

* The definition of earnings per share has been updated to be calculated on the average number of shares for the period instead of on the number of shares at the end of the period. Comparative figures can therefore be adjusted.

Significant events during the first half of 2026

During the first half of 2026, Prostatype Genomics continued to consolidate and further develop the company's commercial and scientific position, with a particular focus on the strategically important U.S. market and on strengthening the clinical evidence for the prognostic genomic test Prostatype®.

Publication of U.S. validation study

The clinical evidence was further strengthened with the publication of the company's U.S. validation study for Prostatype® in the medical journal Prostate Cancer and Prostatic Diseases. The study, conducted in collaboration with Veteran Affairs and Cedars-Sinai Health System, included a diverse patient population and demonstrated once again that the test demonstrates strong and significant prognostic ability to support clinical decisions in prostate cancer diagnostics. This publication further strengthens the evidence base in the United States and contributes to increased clinical credibility in the most important international market.

Loan financing

In December 2025 and January 2026, the company was provided with additional financial flexibility through the signing of short-term loans totalling 10 MSEK, including loans from both major shareholders and external lenders. The financing aims to secure short-term working capital without an immediate dilution effect for the shareholders. An additional loan of 2.5 MSEK was drawn from the facility pending the decision on the financing package 2026.

Decision on financing package 2026

On June 29, the board of directors resolved, based on the authorization granted by the annual general meeting on June 22, 2026, to carry out a preferential rights issue of units of a maximum of approx. 47.4 MSEK before transaction costs. The financing package was designed in three stages: the initial preferential rights issue followed by two possible capital raises through the warrants of series TO6 and TO7. Each unit consisted of eight shares, two warrants of series TO6 free of charge and four warrants of series TO7 free of charge. The subscription price was set at 0.80 SEK per unit, corresponding to 0.10 SEK per share, and the subscription period to July 9–23, 2026. The purpose of the preferential rights issue was to finance the continued Medicare approval process as well as commercialization activities in the U.S. and Europe.

At the time of the resolution, the preferential rights issue was covered by subscription commitments and bottom guarantee commitments totalling 70 percent of the issue amount, corresponding to approx. 33.2 MSEK.



Significant events after the end of the period

Preferential rights issue 2026 completed

On July 8, the company entered into an agreement for an additional guarantee commitment in the form of a top-down guarantee of approximately 10.1 MSEK. The rights issue was thus prior to the subscription period covered by subscription commitments as well as bottom and top-down guarantee commitments totaling approx. 43.2 MSEK, corresponding to approximately 91.3 percent of the maximum issue amount.

The outcome of the preferential rights issue, which had a subscription period from 9 to 23 July, showed that approximately 79.1 percent of the preferential rights issue was subscribed for with and without the support of unit rights. A top-down guarantee commitment of approx. 9.9 MSEK was activated to achieve a total subscription of 100 percent, and the bottom guarantee commitment did not need to be used. Through the preferential rights issue, the company received approx. 47.4 MSEK before transaction costs and a total of 473,514,568 shares, 118,378,642 warrants of series TO6 and 236,757,284 warrants of series TO7 were issued. After the preferential rights issue, the number of shares in the company amounted to 532,703,889.

Following the preferential rights issue, the board of directors resolved on a directed issue of 3,423,452 units as compensation for guarantee commitments and work performed in connection with the preferential rights issue, i.e. 27,387,616 shares, 6,846,904 warrants of series TO6 and 13,693,808 warrants of series TO7.

Following registration of the directed share issue, the total number of shares in the company amounts to 560,091,505 and the share capital to SEK 56,009,150.50, which means that prior to steps two and three of the financing package, the number of outstanding warrants of series TO6 amounts to 125,225,546 and of series TO7 to 250,451,092.

The warrants of series TO6 can be exercised during the period 1–15 September 2026 at an exercise price of 0.10 SEK per share and may, upon full exercise, provide the company with approximately 12.5 MSEK before transaction costs, including the TO6 issued in connection with the directed share issue.

The exercise period for the warrants of series TO7 is primarily event-driven and based on the receipt of Medicare approval. The exercise period of ten trading days shall then commence three trading days after the company has announced the approval, but no earlier than September 1 and no later than December 7, 2026. The exercise price shall correspond to 70 percent of the volume-weighted average price (VWAP) of the company's share during the ten trading days preceding the announcement, however, not less than 0.10 SEK and not more than 0.20 SEK per share.

If Medicare approval has not been granted and no exercise period has been determined in accordance with the above, the exercise period shall instead run from 7 to 21 December 2026. The exercise price shall then correspond to 70 percent of the volume-weighted average price (VWAP) of the company's share during the ten trading days ending two days prior to the start of the exercise period, with the same minimum and maximum exercise price.

At full exercise at the highest exercise price, TO7 can provide the company with approx. 50.1 MSEK before transaction costs, including the TO7 issued in connection with the directed share issue.

CEO Fredrik Rickman comments

During the first half of 2026, we further strengthened the scientific basis for Prostatype® in our most important market. The publication of our U.S. validation study represents the period's most important operational progress and provides us with a stronger basis for both clinical use and reimbursement-based commercialization in the U.S. In parallel, work on the Medicare process has continued, including through a physical meeting during the second quarter. Although the process has taken longer than we would have liked, our assessment remains that the conditions for an approval are good.

The U.S. validation study was conducted under the leadership of Professor Stephen Freedland at Cedars-Sinai and in collaboration with the Durham Veterans Affairs Healthcare System. The study included a diverse patient population with a significant proportion of African American patients and showed that Prostatype® has a strong and significant prognostic ability to identify those men who are at high risk of dying from prostate cancer. The test also showed significantly better performance than existing clinical prognostic tools.

It is particularly significant that no significant difference in the test's performance was observed between African American and Caucasian patients. The results thus strengthen the image of Prostatype® as a robust decision support for use in a broad U.S. patient population. The study's Decision Curve Analysis also showed that the test can provide concrete clinical benefit by improving the basis for treatment decisions – both by identifying patients who need early treatment and by reducing the risk of unnecessary radical treatment.

The fact that these results have now been published in the medical journal Prostate Cancer and Prostatic Diseases is important from both a clinical and commercial perspective. Evidence generated in the U.S. and in a patient population that reflects the U.S. market is of great importance for acceptance among physicians and healthcare providers. It is also relevant for the work to establish a broader reimbursement-based use of Prostatype®.

Our primary focus continues to be the process for reimbursement from Medicare. Since the application was submitted in September 2024, we have continuously answered supplementary questions and conducted a constructive dialogue during the process. During the second quarter of this year, we held a physical meeting with Medicare. The timing of a final decision is governed by processes at the U.S. authorities and therefore cannot be predicted with certainty. However, based on the dialogue that has been conducted and the work that has been carried out, we continue to believe that it is reasonable that an approval can be obtained in 2026.

In recent years, we have at the same time built up the structures required for broader commercialization in the U.S. We have established laboratory and billing partners, Prostatype® is used clinically at selected U.S. hospitals, and we are in dialogues about a future commercial scale-up. This means that we already have an operational basis to start from when the reimbursement is in place. Within the existing regulatory framework, the reimbursement level amounts to 3,783 USD per completed test, which illustrates the commercial potential that a broader use can entail. At the same time, the actual commercial development will depend on how quickly the test is integrated into the clinics'

> The publication of our U.S. validation study represents the period's most important operational progress and provides us with a stronger basis for both clinical use and reimbursement-based commercialization in the U.S.

workflows and the use can be scaled up.

A significant part of the work during the period was related to securing the company's continued financing. A capital raise is not in itself an operational advance, its importance lies in the conditions it creates to move the Medicare process forward and convert our scientific and commercial basis into increased clinical use and future revenues.

On June 29, the board of directors therefore decided to carry out a preferential rights issue of units. After the end of the period, the issue was subscribed to 100 percent, supported by subscription commitments and top-down guarantee commitments, and the company received 47.4 MSEK before transaction costs. The capital will be used, among other things, to move further forward in the Medicare process, prepare for the commercial scale-up in the U.S., repay previously raised bridge financing and handle certain outstanding debts. The warrants of series TO6 and
TO7 that were issued can provide the company with additional capital, but the outcome depends on the extent to which the warrants are exercised.

I would like to thank the shareholders who participated in the issue and thereby gave the company the opportunity to continue working towards our operational and commercial goals. At the same time, I am aware of the significant dilution that the issue entails for existing shareholders. This entails a clear responsibility for us to prioritize resources carefully and convert the capital provided into concrete progress.

Our priorities for the remainder of 2026 are clear: to progress forward in the Medicare process towards a decision, maintain commercial readiness in the U.S. and use the company's resources with great discipline. A Medicare approval would mean a decisive change in the conditions for Prostatype® in the U.S. market and enable us to move from preparatory establishment to focused commercial scale-up.

The expected publication of results from the long-term study with Prostatype® and the ongoing broadening of the product's area of use also represent exciting opportunities for further value creation in the company during the rest of the year.

In conclusion, I would like to thank our employees, clinical partners and shareholders for your continued work, commitment and trust.

Fredrik Rickman
CEO Prostatype Genomics AB
Nacka Strand, 31 August 2026



Key figures

Group

TSEK	2026 Jan-Jun	2025 Jan-Jun	2025 Full year
Net sales	457	246	594
EBITDA	-16,382	-18,971	-36,751
Total Assets	39,912	43,840	50,862
Total Equity	6,548	36,484	26,529
Net cash flow	-8,681	3,517	-330
Equity/Assets-ratio	16%	83%	52%
Average number of employees	7	6	7
Equity per share, SEK	0.11	0.99	0.45
Earnings per share, SEK *			
- Before and after dilution	-0.29	-1.42	-1.32
Number of shares at the end of the period	59,189,321	37,000,265	59,189,321
Number of shares at the end of the period after full dilution	61,836,321	59,624,054	59,189,321
Average number of shares for the period	59,189,321	16,846,750	33,783,778

* The definition of earnings per share has been updated to be calculated on the average number of shares for the period instead of on the number of shares at the end of the period. Comparative figures can therefore be adjusted.

Definition of key ratios

Equity/Assets ratio	Equity / total assets
Equity per share	Equity / number of shares by period closing
Earnings per share	Net profit/loss for the year / average number of shares for the period
Diluted earnings per share	Net profit/loss for the year / (average number of shares + warrants for the period)

Financial development

First half of 2026

Net sales and results

Net sales for the first half of 2026 amounted to 457 TSEK (246). The group is still in the initial phase of commercialization, and thus the net sales is in line with expectations.

Operation profit/loss for the company (EBIT) and operating profit before depreciation and amortization (EBITDA) amounted to -18,856 TSEK (-20,256) and -16,382 TSEK (-18,971), respectively. The company's costs mainly consist of research, testing, personnel and commercialization, with the main focus on preparations ahead of a U.S. launch.

Earnings per share for the period amounted to -0.29 SEK (-1.42).

Investments

The investments mainly relate to product development in and towards the United States and amount to a total of 240 TSEK (1,329).

Cash flow and liquid assets

Net cash flow during the period amounted to -8,681 TSEK (3,517). The group's cash and cash equivalents at the end of the period amounted to 392 TSEK (12,932).

The company's financial position was strengthened during the period through short-term loans from shareholders and external parties.

The parent company

The parent company's income and operating result for the period amounted to 574 TSEK (246) and -13,559 TSEK (-13,210), respectively. The company invested 240 TSEK (1,329) in product development and financed subsidiaries with 4,256 TSEK (4,046). Net cash flow amounted to -8,150 TSEK (3,163) and cash and cash equivalents at the end of the period amounted to 317 TSEK (12,465).

The share

The company's share is listed on the NASDAQ First North Growth Market under the symbol PROGEN, and it is traded with ISIN code SE0023261532.

On 30 June 2026, the share capital amounted to 5,918,931.64 SEK (3,700,027.50) distributed over 59,189,321 shares (37,000,265). The increase in due to the preferential rights issues conducted during the second half of 2025. All shares are issued and fully paid.

In connection with the preferential rights issue resolved on 29 June 2026, which had a subscription period in July 2026 with a subsequent compensation issue, a total of 500,902,184 shares were issued. At the time of the report, the number of shares amounts to 560,091,505 shares. In the same issue, a total of 125,225,546 warrants of series TO6 and 250,451,092 warrants of series TO7 were issued, both with a subscription period during the second half of 2026.

Since March 13, 2025, the company's share is also available for trading on the OTCQB Venture Market in the U.S., which means that the share there can be traded in parallel with its listing on Nasdaq First North in Stockholm, during U.S. trading hours, with a U.S. ticker (OTCQB: PGABF) and pricing in USD. The share is thus not listed in the U.S., it can be traded in the U.S. through the OTCQB service.

A list of the largest shareholders can be found on the company's website (www.prostatypegenomics.com).

The balance sheet

At the end of the period, the group had intangible fixed assets of 37,674 TSEK (28,517) and cash and cash equivalents of 392 TSEK (12,932). The group's equity amounted to 6,548 TSEK (36,484) and outstanding short-term loans amounted to 12,525 TSEK (0).

All outstanding loans were repaid after the end of the period in connection with the preferential rights issue that was completed in July 2026.

The group's intangible assets mainly represent values for expenses, development work, licenses and patents regarding the company's product. Development expenses and patents are written off on a straight-line basis over 10 years.

Liquidity, financing, capital requirements

After the end of the period, the preferential rights issue of units resolved by the board of directors on June 29, 2026, was completed. The preferential rights issue was subscribed to 100 percent, supported by subscription commitments and top guarantee commitments, and provided the company with approx. 47.4 MSEK before transaction costs.

However, the board of directors continues to make the assessment that the group, until a positive operating cash flow is reached, is dependent on additional capital injections.

Based on ongoing financing activities, it is the board's assessment that the group will secure the liquidity required for the needs of the business. The board of directors works proactively to secure growth capital through a combination of debt financing, new issues and strategic collaborations to accelerate commercialization. It is the board's overall conclusion that these measures will ensure continued operations, which is why the report is prepared with the going concern assumption.

However, the board of directors would like to draw attention to the fact that if the necessary additional financing is not realised, this will constitute a material uncertainty factor for the group's ability to continue operations over the next 12 months.

Forward-looking statements

Certain statements in this report are forward-looking and actual results may differ materially. In addition to the factors discussed, other factors may have an impact on actual outcomes. Such factors include developments for customers, competitors, effects of economic and market conditions, national and international laws and regulations, tax regulations, fluctuations in exchange rates and interest rates and political risks.

Profit & loss

Consolidated income statement

TSEK	2026 Jan-Jun	2025 Jan-Jun	2025 Full year
Net sales	457	246	594
Own work capitalized	209	-	-
Other operating income	-	-	3
Total income	**666**	**246**	**597**
Research and development cost	-717	-420	-1,464
Other external costs	-8,467	-11,311	-20,798
Staff cost	-7,306	-7,438	-15,225
Depreciation and impairment of tangible and intangible fixed assets	-2,204	-1,095	-2,187
Other operating expenses	-558	-47	139
Total operating costs	**-19,252**	**-20,311**	**-39,535**
Operating profit/loss (EBIT)	**-18,586**	**-20,065**	**-38,938**
Interest income and similar items	0	0	90
Interest expense and similar items	-549	-227	-1,615
Currency effects	1,815	-3,628	-4,041
Profit/loss after financial items	**-17,320**	**-23,920**	**-44,503**
Current tax	-	-	-
Net profit/loss for the period	**-17,320**	**-23,920**	**-44,503**

Balance

Consolidated balance sheet in summary

TSEK	2026-06-30	2025-06-30	2025-12-31
ASSETS			
Non-current intangible assets	37,674	28,517	39,285
Non-current tangible assets	418	482	452
Non-current financial assets	485	471	485
Total non-current assets	**38,577**	**29,471**	**40,221**
Inventory	93	165	78
Other current receivables	850	1,273	1,495
Cash and bank	392	12,932	9,068
Total current assets	**1,335**	**14,370**	**10,641**
Total assets	**39,912**	**43,840**	**50,862**
Equity and liabilities			
Share capital	5,919	3,700	5,919
Other capital	211,351	204,430	211,817
Other equity including net profit/loss for the period	-210,722	-171,646	-191,206
Total equity	**6,548**	**36,484**	**26,529**
Non-current liabilities	-	-	-
Current liabilities	33,364	7,356	24,333
Total liabilities	**33,364**	**7,356**	**24,333**
Total equity and liabilities	**39,912**	**43,840**	**50,862**
Pledged securities	-	3,612	-
Contingent liabilities	-	-	-

Cash

Consolidated cash flow statement

TSEK	2026 Jan-Jun	2025 Jan-Jun	2025 Full year
Profit/loss after financial items	-17,320	-23,920	-44,503
Adjustments for items not included in cash flow etc.	1,681	4,948	7,719
Cash flow from operating activities before changes in working capital	**-15,639**	**-18,972**	**-36,785**
Change in inventory	-14	-70	16
Change in operating receivables	652	490	264
Change in operating liabilities	827	1,473	12,703
Changes in working capital	**1,464**	**1,892**	**12,983**
Cash flow from operating activities	**-14,175**	**-17,079**	**-23,801**
Investments in intangible assets	-209	-1,195	-13,182
Investments in tangible assets	-32	-229	-258
Change in financial assets	-	94	81
Cash flow from investment activities	**-240**	**-1,329**	**-13,359**
Share issue proceeds, net	-466	21,992	31,597
Loans raised	6,500	5,250	10,550
Loans amortized	-300	-5,317	-5,317
Cash flow from financing activities	**5,734**	**21,925**	**36,831**
Cash flow for the period	**-8,681**	**3,517**	**-330**
Cash and cash equivalents at the beginning of the period	9,068	9,420	9,420
Exchange differences cash and cash equivalents	5	-4	-23
Cash and cash equivalents at the end of the period	**392**	**12,932**	**9,068**

Equity

Consolidated changes in equity

TSEK	Share capital	Other capital/ premium reserves	Other equity including net profit/ loss for the year	Total equity
Opening balance 2025-01-01	**670**	**183,687**	**-150,888**	**33,469**
New share issue	3,030	27,136	-	30,165
Issue expenses	-	-6,392	-	-6,392
Exchange differences	-	-	3,162	3,162
Profit/loss for the period	-	-	-23,920	-23,920
Closing balance 2025-06-30	**3,700**	**204,430**	**-171,646**	**36,484**
New share issue	2,219	9,319	-	11,538
Issue expenses	-	-1,933	-	-1,933
Exchange differences	-	-	1,023	1,023
Profit/loss for the period	-	-	-20,583	-20,583
Closing balance 2025-12-31	**5,919**	**211,817**	**-191,206**	**26,529**
Opening balance 2026-01-01	**5,919**	**211,817**	**-191,206**	**26,529**
New share issues	-	-	-	-
Issue expenses	-	-466	-	-466
Exchange differences	-	-	-2,195	-2,195
Profit/loss for the period	-	-	-17,320	-17,320
Closing balance 2026-06-30	**5,919**	**211,351**	**-210,722**	**6,548**

The share capital of 5,918,931.64 SEK (3,700,027.50) is distributed over 59,189,321 shares (37,000,265).

Parent company

Parent company condensed financial statements

Income statement

TSEK	2026 Jan-Jun	2025 Jan-Jun	2025 Full year
Income	574	246	485
Operating expenses	-11,975	-12,412	-23,715
Depreciation, amortization and impairment	-2,158	-1,044	-2,089
Operating profit/loss	**-13,559**	**-13,210**	**-25,319**
Financial items	-7,560	-6,811	-9,327
Profit/loss after financial items	**-21,119**	**-20,021**	**-34,647**
Taxes	-	-	-
Net profit/loss for the period	**-21,119**	**-20,021**	**-34,647**

Balance sheet

TSEK	2026-06-30	2025-06-30	2025-12-31
Non-current assets	37,481	30,132	43,633
Current assets excl. cash and cash equivalents	11,042	6,214	7,323
Cash and cash equivalents	317	12,465	8,467
Total Assets	**48,839**	**48,812**	**59,423**
Equity	18,298	44,902	39,883
Non-current liabilities	**-**	**-**	-
Current liabilities	30,541	3,909	19,540
Total equity and liabilities	**48,839**	**48,812**	**59,423**

Cash flow statement

TSEK	2026 Jan-Jun	2025 Jan-Jun	2025 Full year
Cash flow from operating activities	-9,388	-13,387	-14,801
Cash flow from investing activities	-4,496	-5,375	-22,866
Cash flow from financing activities	5,734	21,925	36,831
Cash flow for the period	**-8,150**	**3,163**	**-835**
Cash balance at the end of the period	317	12,465	8,467

Changes in equity

TSEK	Share capital	Other restricted capital	Develop-ment fund	Share Premium	Profit/loss brought forward	Total
Opening balance 2025-01-01	**670**	**13**	**12,996**	**183,674**	**-156,203**	**41,150**
New share issues	5,248	-13	-	36,468	-	41,703
Issue expenses	-	-	-	-8,325	-	-8,325
Change in development fund	-	-	-1,857	-	1,857	-
Profit/loss for the period	-	-	-	-	-34,647	-34,647
Closing balance 2025-12-31	**5,919**	**-**	**11,140**	**211,817**	**-188,993**	**39,883**
Issue expenses	-	-	-	-466	-	-466
Change in development fund	-	-	20,111	-	-20,111	-
Profit/loss for the period	-	-	-	-	-21,119	-21,119
Closing balance 2026-06-30	**5,919**	**-**	**31,251**	**211,351**	**-230,223**	**18,298**

General information

Company information

Prostatype Genomics AB with organization number 556726-0285 is a limited company registered in Sweden, domiciled in Stockholm. The address is Augustendalsvägen 20, SE-131 52 Nacka Strand.

The company is engaged in the research and development of medical devices and the sale of these.

Prostatype® is the result of more than fifteen years of research into the genomics of prostate cancer. The company was founded in 2007 as a spin off from Cancer Center Karolinska (Karolinska Institutet, Stockholm). The result was the development of the today CE-marked and market ready product Prostatype® Test System. Prostatype® is a test for prognosis that has been developed to provide the complementary information that is often needed for the selection of the optimal treatment strategy for each patient. The test analyzes the gene expression in cancer cells from prostate tissue and gives, in combination with an advanced algorithm and data analysis, decision support for optimal treatment of individual patients once prostate cancer has been confirmed. Aided by AI (Artificial Intelligence) technology, the gene test of Prostatype Genomics makes it possible to make a better prognosis and to classify the patient's illness into different risk types. In that way the company can reduce the risk of over- or under treatment, which in many cases lead to great discomfort for the patient. Prostatype® is today the only genetic test for prostate cancer that is available in kit format. The product is also very scalable in terms of volume due to the algorithm that forms the basis of the test.

All figures in the report are in thousands of Swedish kronor (TSEK) if not otherwise specified. Amounts or information in parentheses refer to the corresponding period of the previous year. Rounding differences may therefore occur.

Accounting principles

The report has been prepared in accordance with the Swedish Annual Accounts Act and he Swedish Accounting Standards Board's general guidelines BFNAR 2012:1 Annual Report and Consolidated Financial Statements (K3) issued by the Swedish Accounting Standards Boards (BFN).The accounting policy for the company complies with applied accounting principles for the most recent published annual report.

Transactions with related parties

Shareholder loans

In December 2025 and January 2026, the company signed short-term loan agreements with board members and major shareholders, of which 2.0 MSEK with board members, Håkan Englund with 1.5 MSEK, Anders Lundberg with 0.2 MSEK, Michael Häggman with 0.2 MSEK and Jörgen Dahlström with 0.1 MSEK, and newly elected chairman of the board Anders Liljeblad with 0.5 MSEK. The loans have a fixed period interest rate of 15% and run until June 30, 2026. The loans were subscribed for privately or via controlled companies and have all been repaid after the end of the period in connection with the preferential rights issue that was completed in July 2026.

Consultancy fees

Board member Mattias Prage is employed at Advokatbyrån Lindahl KB, which the company engages for advice on legal issues and company administration. During the year, Lindahl invoiced the company 369 TSEK (437).

Board member Jörgen Dahlström is CEO of Mercodia AB, which has purchased consulting services from the company for 165 TSEK (0).

Material risks and uncertainties in summary

A description of the most significant market and business related risks can be found in the annual report for 2025, as well as in the prospectus submitted and published on the company's website www.prostatypegenomics.com

Valuation of assets

The company's product, Prostatype®, is in a commercialization phase. There is, as with all businesses, a long-term risk that objectives will not be achieved within the time frame on which the group's forecasts are based. If the sales do not reach the set goals so that the assumed cash flows do not occur at the rate assumed by the board and company management or are alternatively postponed further in time, or if other assumptions that formed the basis of the impairment test carried out by the company management would change in a negative way, this may lead to the intangible assets being written down at a faster rate than planned.

Other information

Financial calendar

Year-end report 2026: 2027-02-11

The company's financial reports are available on prostatypegenomics.com

Review

This interim report has not been subject to review by the company's auditors.

Certified Advisor

Tapper Partners AB
Telephone: +46 (0)70-44 010 98
Email: ca@tapperpartners.se

Publication

This information is such information that Prostatype Genomics AB is obliged to make public according to the EU's market abuse regulation. The information was submitted, through the contact person below, for publication on 31 August, 2026.

Fredrik Rickman, CEO
fredrik.rickman@prostatypegenomics.com

Signing of the report

The board and the CEO assure that the interim report provides a fair overview of the group's and the parent company's operations, balance and results, and describes the significant risks and uncertainty factors that the group is facing.

Nacka Strand, 31 August, 2026

Anders Liljeblad
Chairman

Anders Lundberg
Board member

Håkan Englund
Board member

Michael Häggman
Board member

Mattias Prage
Board member

Jörgen Dahlström
Board member

Fredrik Rickman
CEO

Phone: +46 (0)8-20 87 00
Website: www.prostatypegenomics.com

Prostatype Genomics AB

Augustendalsvägen 20, SE-131 52 Nacka Strand
Phone: +46 (0)8-20 87 00
Website: www.prostatypegenomics.com